The Significance of Ras Activity in Pancreatic Cancer Initiation
- PMID: 26929740
- PMCID: PMC4753162
- DOI: 10.7150/ijbs.15020
The Significance of Ras Activity in Pancreatic Cancer Initiation
Abstract
The genetic landscape of pancreatic cancer shows nearly ubiquitous mutations of K-RAS. However, oncogenic K-Ras(mt) alone is not sufficient to lead to pancreatic ductal adenocarcinoma (PDAC) in either human or in genetically modified adult mouse models. Many stimulants, such as high fat diet, CCK, LPS, PGE2 and others, have physiological effects at low concentrations that are mediated in part through modest increases in K-Ras activity. However, at high concentrations, they induce inflammation that, in the presence of oncogenic K-Ras expression, substantially accelerates PDAC formation. The mechanism involves increased activity of oncogenic K-Ras(mt). Unlike what has been proposed in the standard paradigm for the role of Ras in oncogenesis, oncogenic K-Ras(mt) is now known to not be constitutively active. Rather, it can be activated by standard mechanisms similar to wild-type K-Ras, but its activity is sustained for a prolonged period. Furthermore, if the level of K-Ras activity exceeds a threshold at which it begins to generate its own activators, then a feed-forward loop is formed between K-Ras activity and inflammation and pathological processes including oncogenesis are initiated. Oncogenic K-Ras(mt) activation, a key event in PDAC initiation and development, is subject to complex regulatory mechanisms. Reagents which inhibit inflammation, such as the Cox2 inhibitor celecoxib, block the feed-forward loop and prevent induction of PDAC in models with endogenous oncogenic K-Ras(mt). Increased understanding of the role of activating and inhibitory mechanisms on oncogenic K-Ras(mt) activity is of paramount importance for the development of preventive and therapeutic strategies to fight against this lethal disease.
Keywords: K-RAS.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures
![Fig 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4753162/bin/ijbsv12p0338g001.gif)
![Fig 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4753162/bin/ijbsv12p0338g002.gif)
![Fig 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4753162/bin/ijbsv12p0338g003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4753162/bin/ijbsv12p0338g005.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4753162/bin/ijbsv12p0338g006.gif)
Similar articles
-
The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells.Carcinogenesis. 2011 Apr;32(4):488-95. doi: 10.1093/carcin/bgr007. Epub 2011 Jan 24. Carcinogenesis. 2011. PMID: 21262926 Free PMC article.
-
Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53.Oncogene. 2017 Jun 1;36(22):3149-3158. doi: 10.1038/onc.2016.461. Epub 2016 Dec 19. Oncogene. 2017. PMID: 27991926 Free PMC article.
-
Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.Gastroenterology. 2014 Nov;147(5):1119-33.e4. doi: 10.1053/j.gastro.2014.08.002. Epub 2014 Aug 12. Gastroenterology. 2014. PMID: 25127677
-
MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention.Semin Cancer Biol. 2019 Feb;54:63-71. doi: 10.1016/j.semcancer.2017.11.020. Epub 2017 Dec 2. Semin Cancer Biol. 2019. PMID: 29199014 Free PMC article. Review.
-
Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.Cancer Metastasis Rev. 2013 Jun;32(1-2):147-62. doi: 10.1007/s10555-012-9396-2. Cancer Metastasis Rev. 2013. PMID: 23085856 Review.
Cited by
-
Targeting KRAS in pancreatic cancer.Oncol Res. 2024 Apr 23;32(5):799-805. doi: 10.32604/or.2024.045356. eCollection 2024. Oncol Res. 2024. PMID: 38686056 Free PMC article. Review.
-
Weight-centric prevention of cancer.Obes Pillars. 2024 Mar 5;10:100106. doi: 10.1016/j.obpill.2024.100106. eCollection 2024 Jun. Obes Pillars. 2024. PMID: 38495815 Free PMC article. Review.
-
Early elevations of RAS protein level and activity are critical for the development of PDAC in the context of inflammation.Cancer Lett. 2024 Apr 1;586:216694. doi: 10.1016/j.canlet.2024.216694. Epub 2024 Feb 1. Cancer Lett. 2024. PMID: 38307409
-
Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy.Nat Cancer. 2024 Mar;5(3):400-419. doi: 10.1038/s43018-023-00720-x. Epub 2024 Jan 24. Nat Cancer. 2024. PMID: 38267627
-
Key transcriptional effectors of the pancreatic acinar phenotype and oncogenic transformation.PLoS One. 2023 Oct 5;18(10):e0291512. doi: 10.1371/journal.pone.0291512. eCollection 2023. PLoS One. 2023. PMID: 37796967 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous